Cargando…
Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR
TweakR is a TNF receptor family member, whose natural ligand is the multifunctional cytokine TWEAK. The growth inhibitory activity observed following TweakR stimulation in certain cancer cell lines and the overexpression of TweakR in many solid tumor types led to the development of enavatuzumab (PDL...
Autores principales: | Purcell, James W., Kim, Han K., Tanlimco, Sonia G., Doan, Minhtam, Fox, Melvin, Lambert, Peter, Chao, Debra T., Sho, Mien, Wilson, Keith E., Starling, Gary C., Culp, Patricia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884146/ https://www.ncbi.nlm.nih.gov/pubmed/24409185 http://dx.doi.org/10.3389/fimmu.2013.00505 |
Ejemplares similares
-
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb
por: Chao, Debra T., et al.
Publicado: (2012) -
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells
por: Ye, Shiming, et al.
Publicado: (2017) -
Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts
por: de Plater, Ludmilla, et al.
Publicado: (2014) -
Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies
por: Chicheportiche, Yves, et al.
Publicado: (2002) -
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
por: Woo, Jacky, et al.
Publicado: (2013)